Skip to main content

Antimicrobial Resistance clinical trials at UCSF

3 in progress, 2 open to eligible people

Antimicrobial resistance means bacteria become immune to antibiotics. At UCSF, there are trials recruiting people to study how to fight bacteria that are resistant. One trial looks at how antibiotic use after eye surgeries affects resistance. Another trial studies a drug called azithromycin to help children in Niger. The goal is to find ways to reduce the impact of antimicrobial resistance.

Showing trials for
  • Antibiotic Resistance In Eye Surgeries

    open to eligible people ages 18-85

    In this study, the investigators seek to determine the effect of antibiotic use post-surgery on antimicrobial resistance. The investigators will be studying adults (aged 18 or older) who will undergo eye surgery at University of California, San Francisco (UCSF). We seek to gain a better understanding of how antibiotic use during the perioperative period influences local and systemic antibiotic resistance at the individual level.

    San Francisco, California

  • Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)

    open to eligible people ages 1 month and up

    The MORDOR trial found that biannual distribution of azithromycin to children 1-59 months old reduced child mortality. The World Health Organization (WHO) released conditional guidelines for this intervention, which include targeting azithromycin distributions to children 1-11 months of age in high mortality settings. The proposed trial aims to demonstrate and evaluate large-scale implementation of azithromycin to children aged 1-11 months old in the context of a programmatic setting while monitoring mortality and resistance antimicrobial resistance.

    San Francisco, California

  • Ocular Rosacea Biome Study

    Sorry, not yet accepting patients

    Ocular rosacea is an inflammatory disease of the eyelids and ocular surface. Like the facial disease, the ocular condition is chronic and recurrent. Sequelae of ocular rosacea vary from mild to severe. Ocular rosacea may cause chronic eye redness, blepharitis, recurrent chalazia, dry eye, corneal erosion, corneal vascularization, and corneal ulceration. Rosacea affecting the cornea can result in vision loss. Prescription eye drops and ointments can be used topically to control mild ocular rosacea. However, severe disease, or rosacea that is not well controlled with local treatments is treated systemically. The most commonly used systemic treatment for rosacea is the bacteriostatic antibiotic doxycycline. Rosacea treatment doses of doxycycline vary widely. Treatment-dose doxycycline for systemic infections is 100mg twice a day. However, as rosacea is considered an inflammatory disease, doxycycline is often dosed at what is termed, sub-microbial dose doxycycline (SDD). Initially introduced in the oral medicine literature, SDD are doses 40mg and lower because systemic administration at this dose does not appear to alter the oral mucosa flora or increase resistance rates when given long-term for periodontal disease. Whereas 100mg doxycycline, even when given short term, may increase the percentage of culturable nasopharyngeal flora that is resistant to doxycycline. The FDA does not categorize SDD an antibiotic, stating this dosing is expected to exhibit only anti-inflammatory activity.

    San Francisco, California

Our lead scientists for Antimicrobial Resistance research studies include .

Last updated: